Today we announced the close of a public offering with ~$60M in gross proceeds to fund corporate activities and post-Phase 3 planning for RZ358 in congenital hyperinsulinism, in addition to initiation and conduct of a potential late-stage, registrational, clinical study of RZ358 in patients with tumor hyperinsulinism: https://bit.ly/3VX6wei
Rezolute, Inc.
Biotechnology Research
Redwood City, California 5,213 followers
Rezolute is developing transformative therapeutics for rare and metabolic diseases.
About us
Rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases. For more information, visit: www.rezolutebio.com.
- Website
-
http://www.rezolutebio.com
External link for Rezolute, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Redwood City, California
- Type
- Public Company
Locations
-
Primary
275 Shoreline Dr.
Ste. 500
Redwood City, California 94065, US
Employees at Rezolute, Inc.
-
Gil Labrucherie
-
Jon Postlethwaite, PhD.
Biotech Supply Chain Executive | Global Launch Readiness & Execution | Logistics & Trade Compliance | Packaging & Labeling | 3PL | Supply Planning
-
Jenny Watson
CMC and Quality Leader
-
Jeffrey Breit, Ph.D.
Vice President, Drug Discovery and Pharmaceutical Sciences
Updates
-
An evidence-based estimate of congenital hyperinsulinism (cHI) birth prevalence is essential to improve diagnosis and patient management, to drive clinical research and the development of new treatments, and to inform public policy. With this recent publication we now have a better understanding of the true global impact of this rare disease. Thank you to the research and advocacy communities for their work on this important topic! https://bit.ly/3Vp0bXo
-
We’re thrilled to have been able to participate in this year’s Congenital Hyperinsulinism International Family Conference! Thank you to the families, physicians and colleagues that made this such a wonderful event, and for the continued support in developing new therapies to treat cHI.
We thank the sponsors of the 2024 Congenital Hyperinsulinism Family Conference Sponsors for their generous support! It was an incredibly enriching and awe-inspiring weekend, filled with valuable insights and information about the latest in hyperinsulinism and hypoglycemia.
-
Join us in NYC at the Jefferies Global Healthcare Conference where Rezolute management will participate in a fireside chat on Thursday, June 6, 2024, at 1:00 p.m. ET. https://bit.ly/4aBCFfq
-
Today we announced positive topline data from our Phase 2 study of RZ402 in patients with diabetic macular edema (DME). Check out the press release to learn more: https://bit.ly/3VbpXzi
-
Today, we reported our fiscal Q3 results and business update. Learn more about our progress here: https://bit.ly/3wyy53D
-
Attending #ACSSpring2024? Check out this presentation by Rezolute's Ian Yates! https://bit.ly/4czGV1g
-
This morning we announced the validation of the potential use of RZ358 in treating NICTH, possibly more than doubling the addressable patient population living with hypoglycemia as a result of tumor hyperinsulinism (HI): https://bit.ly/43lGhQR
-
Did you know? There are ~10,000 individuals globally living with congenital hyperinsulinism. Learn more about our mission to develop a novel therapy that transforms the treatment paradigm: https://bit.ly/4bZqXgk #ShowYourStripes #RareDiseaseDay
-
On #RareDiseaseDay, we come together to show our stripes, raising awareness and support for those living with rare conditions like congenital hyperinsulinism. Join us! #ShowYourStripes